Table 4 Univariate analysis of relapse-free survival for immunohistochemical biomarkers in the test and validation sets

Test

ER

-

308/313

100

2.9 (1.7–4.1)

1

+

208

6.1 (4.1–8.1)

0.70 (0.52–0.93)

0.02

PR

-

279/313

143

3.0 (2.1–3.8)

1

+

136

8.2 (5.0–11.4)

0.58 (0.43–0.78)

0.0003

HER2

-

300/313

240

6.0 (4.4–7.6)

1

+

60

3.6 (2.1–5.1)

1.33 (0.94–1.89)

0.1

EGFR

-

271/313

239

6.0 (4.0–8.0)

1

+

32

1.6 (0.9–2.3)

2.30 (1.49–3.56)

0.0002

Ki-67

-

308/313

140

11.0 (6.5–15.6)

1

+

168

3.6 (2.8–4.4)

1.93 (1.44–2.60)

0.00001

p53

-

307/313

235

6.4 (4.3–8.6)

1

+

72

2.6 (1.9–3.3)

1.59 (1.16–2.18)

0.004

CA IX

-

281/313

234

5.7 (4.0–7.4)

1

+

47

2.5 (1.4–3.6)

1.81 (1.26–2.62)

0.002

CK5/6

-

260/313

238

5.2 (3.8–6.6)

1

+

22

2.5 (0.6–4.3)

1.60 (0.94–2.73)

0.08

Validation

ER

-

288/289

100

2.6 (1.5–3.8)

1

+

188

7.2 (5.8–8.5)

0.68 (0.50–0.92)

0.01

PR

-

268/289

143

3.8 (2.1–5.5)

1

+

125

7.2 (6.1–8.3)

0.73 (0.54–1.00)

0.05

HER2

-

273/289

206

7.0 (5.8–8.2)

1

+

67

2.4 (1.5–3.2)

1.55 (1.11–2.18)

0.01

EGFR

-

257/289

219

6.6 (4.9–8.3)

1

+

38

2.1 (1.3–2.8)

1.81 (1.21–2.70)

0.004

Ki-67

-

289/289

134

7.2 (5.6–8.8)

1

+

155

4.8 (3.0–6.6)

1.27 (0.94–1.70)

0.12

p53

-

286/289

223

6.7 (5.1–8.2)

1

+

63

2.7 (0.5–4.9)

1.40 (0.99–1.97)

0.06

CA IX

-

271/289

227

7.1 (5.4–8.6)

1

+

44

2.3 (1.3–3.2)

1.79 (1.23–2.61)

0.002

CK5/6

-

252/289

237

6.0 (4.3–7.6)

1

+

15

2.4 (1.7–3.1)

1.81 (1.00–3.27)

0.05